Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026
DOI: 10.1002/phar.70116 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Yanting Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Tacrolimus, Cytochrome P-450 CYP3A, Heart Transplantation, Immunosuppressive Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCCIH NIH HHS, Indiana University.
Abstract (Originalsprache)
Background
Tacrolimus is primarily metabolized by Cytochrome P450 (CYP)3A4/5. The Clinical Pharmacogenetics Implementation Consortium recommends increasing the initial dose 1.5‐ to 2‐fold in CYP3A5 expressers to enhance transplant outcomes. Our objective was to investigate the impact of CYP3A5 expresser status on tacrolimus dosing requirements and attainment of target trough concentrations in heart transplant recipients.
Methods
We performed a retrospective cohort analysis of tacrolimus dose, concentration, demographics, CYP3A4/5 genotype, concomitant medications, and biochemical data in heart transplant recipients from December 2020 to August 2023. The primary outcome was the time to first therapeutic trough concentration, compared by CYP3A5 expression status. Secondary outcomes included the tacrolimus dose at target trough and dose‐adjusted tacrolimus trough concentration (C 0 /D). Stepwise multiple regression was performed to account for potential covariates. Moreover, clinical outcomes were assessed at 1‐year post‐transplantation and compared based on CYP3A5 expression status.
Results
Among 33 patients, CYP3A5 expressers (27.3%) required longer to achieve therapeutic trough concentrations (median [Q1, Q3]: expressers: 14 [9.5, 16] days vs. nonexpressers 7.5 [6.0, 11] days; p = 0.0073) and required nearly double the tacrolimus dose to reach target concentrations (10 [5.5, 13] mg/day for expressers vs. 5 [3.3, 5.9] mg/day for nonexpressers; p = 0.0019). Conversely, the C 0 /D was nearly 2‐fold higher in nonexpressers 2.0 [1.6, 3.4] ng/(mL*mg) than expressers (1.1 [0.83, 1.7] ng/(mL*mg); p = 0.0015). Stepwise regression identified route of administration (sublingual vs. oral) at therapeutic trough and initial dose as covariates for all outcomes. All clinical outcomes showed no significant differences based on CYP3A5 expression status, with the exception that poor metabolizers demonstrated higher serum creatinine elevation at 1‐week post‐transplantation ( p = 0.047).
Conclusion
Our findings highlight the impact of CYP3A5 expresser status on the time needed and dosing requirements to attain tacrolimus therapeutic concentrations in heart transplant recipients, suggesting CYP3A5 ‐guided dosing strategies may improve rapid attainment of therapeutic tacrolimus concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Yanting Wu, Michael T Eadon, Roopa A Rao, Todd C Skaar, Emma M Tillman, Tyler Shugg
Förderung
- NIGMS NIH HHS
- NCCIH NIH HHS
- Indiana University
- NIGMS / NIH National Institutes of Health/National Institute of General Medical Sciences
- National Institutes of Health/National Institute of General Medical Science
- National Center for Complementary and Integrative Health
- National Institute of General Medical Sciences
Zitieren
APA
Wu, Y., Eadon, M. T., Schenkelberg, L., Rao, R. A., Skaar, T. C., Tillman, E. M., & Shugg, T. (2026). Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70116
Vancouver
Wu Y, Eadon MT, Schenkelberg L, Rao RA, Skaar TC, Tillman EM, et al. Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70116
BibTeX
@article{Wu2026,
author = {Wu, Yanting and Eadon, Michael T and Schenkelberg, Laurie and Rao, Roopa A and Skaar, Todd C and Tillman, Emma M and Shugg, Tyler},
title = {Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
doi = {10.1002/phar.70116}
}
EUVIMED